Role of inflammasomes and theirregulators in prostate cancer initiation, progression and metastasis

• Autorzy: Veeranki S.
• Języki publikacji: EN

Abstrakty

EN

Prostate cancer is one of the main cancers that affect men, especially older men. Though there has been considerable progress in understanding the progression of prostate cancer, the drivers of its development need to be studied more comprehensively. The emergence of resistant forms has also increased the clinical challenges involved in the treatment of prostate cancer. Recent evidence has suggested that inflammation might play an important role at various stages of cancer development. This review focuses on inflammasome research that is relevant to prostate cancer and indicates future avenues of study into its effective prevention and treatment through inflammasome regulation. With regard to prostate cancer, such research is still in its early stages. Further study is certainly necessary to gain a broader understanding of prostate cancer development and to create successful therapy solutions.

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2013
• Tom: 18
• Numer: 3
• Opis fizyczny: p.355-367,fig.,ref.

Twórcy

autor

Veeranki S.

• Department of Biochemistry and Molecular Biology, University of Louisville, Baxter II, Rm. 117, 580 S. Preston St., KY 40202, USA

Bibliografia

• 1. Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., Lin, C., Leach, C., Cannady, R.S., Cho, H., Scoppa, S., Hachey, M., Kirch, R., Jemal, A. and Ward, E. Cancer treatment and survivorship statistics, 2012. CA. Cancer J. Clin. 62 (2012) 220-241.
• 2. Tewari, A.K. and George, D.J. Novel chemotherapies in development for management of castration-resistant prostate cancer. Curr. Opin. Urol. (2013). DOI: 10.1097/MOU.0b013e32835f7da2.
• 3. De Marzo, A.M., Platz, E.A., Sutcliffe, S., Xu, J., Gronberg, H., Drake, C.G., Nakai, Y., Isaacs, W.B. and Nelson, W.G. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7 (2007) 256- 269.
• 4. Haverkamp, J., Charbonneau, B. and Ratliff, T.L. Prostate inflammation and its potential impact on prostate cancer: a current review. J. Cell Biochem. 103 (2008) 1344-1353.
• 5. Kazma, R., Mefford, J.A., Cheng, I., Plummer, S.J., Levin, A.M., Rybicki, B.A., Casey, G. and Witte, J.S. Association of the innate immunity and inflammation pathway with advanced prostate cancer risk. PLoS One 7 (2012) e51680.
• 6. Kwon, E.M., Salinas, C.A., Kolb, S., Fu, R., Feng, Z., Stanford, J.L. and Ostrander, E.A. Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 20 (2011) 923-933.
• 7. Sfanos, K.S. and De Marzo, A.M. Prostate cancer and inflammation: the evidence. Histopathology 60 (2012) 199-215.
• 8. Stock, D., Groome, P.A. and Siemens, D.R. Inflammation and prostate cancer: a future target for prevention and therapy? Urol. Clin. North Am. 35 (2008) 117-130, vii.
• 9. MacLennan, G.T., Eisenberg, R., Fleshman, R.L., Taylor, J.M., Fu, P., Resnick, M.I. and Gupta, S. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. J. Urol. 176 (2006) 1012- 1016.
• 10. Billis, A., Freitas, L.L., Magna, L.A. and Ferreira, U. Inflammatory atrophy on prostate needle biopsies: is there topographic relationship to cancer? Int. Braz. J. Urol. 33 (2007) 355-360; discussion 361-353.
• 11. Billis, A. and Magna, L.A. Inflammatory atrophy of the prostate. Prevalence and significance. Arch. Pathol. Lab. Med. 127 (2003) 840-844.
• 12. Montironi, R., Vela Navarrete, R., Lopez-Beltran, A., Mazzucchelli, R., Mikuz, G. and Bono, A.V. Histopathology reporting of prostate needle biopsies. 2005 update. Virchows Arch. 449 (2006) 1-13.
• 13. Billis, A. Re: Inflammatory atrophy on prostate needle biopsies: is there topographic relationship to cancer? Int. Braz. J. Urol. 33 (2007) 566-568.
• 14. Schroder, K. and Tschopp, J. The inflammasomes. Cell 140 (2010) 821-832.
• 15. Zitvogel, L., Kepp, O., Galluzzi, L. and Kroemer, G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 13 (2012) 343-351.
• 16. Dunn, J.H., Ellis, L.Z. and Fujita, M. Inflammasomes as molecular mediators of inflammation and cancer: potential role in melanoma. Cancer Lett. 314 (2012) 24-33.
• 17. Guo, Y. and Kyprianou, N. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res. 59 (1999) 1366-1371.
• 18. Winter, R.N., Kramer, A., Borkowski, A. and Kyprianou, N. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. 61 (2001) 1227-1232.
• 19. Bruckheimer, E.M. and Kyprianou, N. Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells. Prostate 53 (2002) 133-142.
• 20. Sasaki, Y., Ahmed, H., Takeuchi, T., Moriyama, N. and Kawabe, K. Immunohistochemical study of Fas, Fas ligand and interleukin-1 beta converting enzyme expression in human prostatic cancer. Br. J. Urol. 81 (1998) 852-855.
• 21. Nikitina, E.Y., Desai, S.A., Zhao, X., Song, W., Luo, A.Z., Gangula, R.D., Slawin, K.M. and Spencer, D.M. Versatile prostate cancer treatment with inducible caspase and interleukin-12. Cancer Res. 65 (2005) 4309-4319.
• 22. Winter, R.N., Rhee, J.G. and Kyprianou, N. Caspase-1 enhances the apoptotic response of prostate cancer cells to ionizing radiation. Anticancer Res. 24 (2004) 1377-1386.
• 23. Hasegawa, M., Kawase, K., Inohara, N., Imamura, R., Yeh, W.C., Kinoshita, T. and Suda, T. Mechanism of ASC-mediated apoptosis: biddependent apoptosis in type II cells. Oncogene 26 (2007) 1748-1756.
• 24. Collard, R.L., Harya, N.S., Monzon, F.A., Maier, C.E. and O’Keefe, D.S. Methylation of the ASC gene promoter is associated with aggressive prostate cancer. Prostate 66 (2006) 687-695.
• 25. Das, P.M., Ramachandran, K., Vanwert, J., Ferdinand, L., Gopisetty, G., Reis, I.M. and Singal, R. Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol. Cancer 5 (2006) 28.
• 26. Gurjar, M.V., DeLeon, J., Sharma, R.V. and Bhalla, R.C. Mechanism of inhibition of matrix metalloproteinase-9 induction by NO in vascular smooth muscle cells. J. Appl. Physiol. 91 (2001) 1380-1386.
• 27. Petrella, B.L., Armstrong, D.A. and Vincenti, M.P. Interleukin-1 beta and transforming growth factor-beta 3 cooperate to activate matrix metalloproteinase expression and invasiveness in A549 lung adenocarcinoma cells. Cancer Lett. 325 (2012) 220-226.
• 28. Nakao, S., Kuwano, T., Tsutsumi-Miyahara, C., Ueda, S., Kimura, Y.N., Hamano, S., Sonoda, K.H., Saijo, Y., Nukiwa, T., Strieter, R.M., Ishibashi, T., Kuwano, M. and Ono, M. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J. Clin. Invest. 115 (2005) 2979-2991.
• 29. Tsuzaki, M., Guyton, G., Garrett, W., Archambault, J.M., Herzog, W., Almekinders, L., Bynum, D., Yang, X. and Banes, A.J. IL-1 beta induces COX2, MMP-1, -3 and -13, ADAMTS-4, IL-1 beta and IL-6 in human tendon cells. J. Orthop. Res. 21 (2003) 256-264.
• 30. Maggio, M., Basaria, S., Ceda, G.P., Ble, A., Ling, S.M., Bandinelli, S., Valenti, G. and Ferrucci, L. The relationship between testosterone and molecular markers of inflammation in older men. J. Endocrinol. Invest. 28 (2005) 116-119.
• 31. Saylor, P.J., Kozak, K.R., Smith, M.R., Ancukiewicz, M.A., Efstathiou, J.A., Zietman, A.L., Jain, R.K. and Duda, D.G. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist 17 (2012) 212-219.
• 32. Vykhovanets, E.V., Shukla, S., MacLennan, G.T., Vykhovanets, O.V., Bodner, D.R. and Gupta, S. Il-1 beta-induced post-transition effect of NFkappaB provides time-dependent wave of signals for initial phase of intrapostatic inflammation. Prostate 69 (2009) 633-643.
• 33. Klein, R.D., Borchers, A.H., Sundareshan, P., Bougelet, C., Berkman, M.R., Nagle, R.B. and Bowden, G.T. Interleukin-1beta secreted from monocytic cells induces the expression of matrilysin in the prostatic cell line LNCaP. J. Biol. Chem. 272 (1997) 14188-14192.
• 34. Lebel-Binay, S., Thiounn, N., De Pinieux, G., Vieillefond, A., Debre, B., Bonnefoy, J.Y. and Fridman, W.H., Pages, F. IL-18 is produced by prostate cancer cells and secreted in response to interferons. Int. J. Cancer 106 (2003) 827-835.
• 35. Veeranki, S., Duan, X., Panchanathan, R., Liu, H. and Choubey, D. IFI16 protein mediates the anti-inflammatory actions of the type-I interferons through suppression of activation of caspase-1 by inflammasomes. PLoS One 6 (2011) e27040.
• 36. Fujita, K., Ewing, C.M., Isaacs, W.B. and Pavlovich, C.P. Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int. J. Cancer 129 (2011) 424-432.
• 37. Veeranki, S. and Choubey, D. Interferon-inducible p200-family protein IFI16, an innate immune sensor for cytosolic and nuclear double-stranded DNA: regulation of subcellular localization. Mol. Immunol. 49 (2012) 567-571.
• 38. Xin, H., Curry, J., Johnstone, R.W., Nickoloff, B.J. and Choubey, D. Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence. Oncogene 22 (2003) 4831-4840.
• 39. Cahu, J., Bustany, S. and Sola, B. Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells. Cell Death Dis. 3 (2012) e446.
• 40. Choubey, D. DNA-responsive inflammasomes and their regulators in autoimmunity. Clin. Immunol. 142 (2012) 223-231.
• 41. Lamkanfi, M. and Dixit, V.M. Inflammasomes and their roles in health and disease. Annu. Rev. Cell Dev. Biol. 28 (2012) 137-161.
• 42. Olsson, J., Drott, J.B., Laurantzon, L., Laurantzon, O., Bergh, A. and Elgh, F. Chronic prostatic infection and inflammation by Propionibacterium acnes in a rat prostate infection model. PLoS One 7 (2012) e51434.
• 43. Shinohara, D.B., Vaghasia, A.M., Yu, S.H., Mak, T.N., Bruggemann, H., Nelson, W.G., De Marzo, A.M., Yegnasubramanian, S. and Sfanos, K.S. A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. Prostate (2013) doi: 10.1002/pros.22648.
• 44. Sahdo, B., Sarndahl, E., Elgh, F. and Soderquist, B. Propionibacterium acnes activates caspase-1 in human neutrophils. APMIS (2012) doi: 10.1111/apm.12035.
• 45. Nakahira, K., Haspel, J.A., Rathinam, V.A., Lee, S.J., Dolinay, T., Lam, H.C., Englert, J.A., Rabinovitch, M., Cernadas, M., Kim, H.P., Fitzgerald, K.A., Ryter, S.W. and Choi, A.M. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 12 (2011) 222- 230.
• 46. Harris, J., Hartman, M., Roche, C., Zeng, S.G., O'Shea, A., Sharp, F.A., Lambe, E.M., Creagh, E.M., Golenbock, D.T., Tschopp, J., Kornfeld, H., Fitzgerald, K.A. and Lavelle, E.C. Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J. Biol. Chem. 286 (2011) 9587-9597.
• 47. Menu, P., Mayor, A., Zhou, R., Tardivel, A., Ichijo, H., Mori, K. and Tschopp, J. ER stress activates the NLRP3 inflammasome via an UPRindependent pathway. Cell Death Dis. 3 (2012) e261.
• 48. Duncan, J.A., Gao, X., Huang, M.T., O'Connor, B.P., Thomas, C.E., Willingham, S.B., Bergstralh, D.T., Jarvis, G.A., Sparling, P.F. and Ting, J.P. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome. J. Immunol. 182 (2009) 6460-6469.
• 49. Abdul-Sater, A.A., Said-Sadier, N., Padilla, E.V. and Ojcius, D.M. Chlamydial infection of monocytes stimulates IL-1beta secretion through activation of the NLRP3 inflammasome. Microbes Infect. 12 (2010) 652-661.
• 50. Babolin, C., Amedei, A., Ozolins, D., Zilevica, A., D'Elios, M.M. and de Bernard, M. TpF1 from Treponema pallidum activates inflammasome and promotes the development of regulatory T cells. J. Immunol. 187 (2011) 1377-1384.
• 51. Johnson, K.E., Chikoti, L. and Chandran, B. HSV-1 infection induces activation and subsequent inhibition of the IFI16 and NLRP3 inflammasomes. J. Virol. (2013) doi: 10.1128/JVI.00082-13.
• 52. Rathinam, V.A., Jiang, Z., Waggoner, S.N., Sharma, S., Cole, L.E., Waggoner, L., Vanaja, S.K., Monks, B.G., Ganesan, S., Latz, E., Hornung, V., Vogel, S.N., Szomolanyi-Tsuda, E. and Fitzgerald, K.A. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat. Immunol. 11 (2010) 395-402.
• 53. Persson, B.E. and Ronquist, G. Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion. J. Urol. 155 (1996) 958-960.
• 54. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. and Tschopp, J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature 440 (2006) 237-241.
• 55. Couillin, I., Vasseur, V., Charron, S., Gasse, P., Tavernier, M., Guillet, J., Lagente, V., Fick, L., Jacobs, M., Coelho, F.R., Moser, R. and Ryffel, B. IL1R1/MyD88 signaling is critical for elastase-induced lung inflammation and emphysema. J. Immunol. 183 (2009) 8195-8202.
• 56. Cohen, T.S. and Prince, A.S. Activation of inflammasome signaling mediates pathology of acute P. aeruginosa pneumonia. J. Clin. Invest. (2013) doi: 10.1172/JCI66142.
• 57. Hrbacek, J., Urban, M., Hamsikova, E., Tachezy, R. and Heracek, J. Thirty years of research on infection and prostate cancer: No conclusive evidence for a link. A systematic review. Urol. Oncol. (2012) doi:10.1016/j.urolonc.2012.01.013.

Uwagi

Rekord w opracowaniu